← All trials
NCT05605093
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 15, 2022
- Primary completion
- Mar 1, 2024
- Completion date
- Mar 1, 2024
- First posted
- Nov 4, 2022
- Last posted
- Nov 25, 2022
- Enrollment
- 1500
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of MinnesotaLead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)Collaborator
- University of CopenhagenOverall official - principal investigator
- University of MinnesotaStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.